Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 205 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: as needed dosing Clear all
Not yet recruiting Phase 4 Interventional

Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery

NCT07600697
View directory record Official record
Conditions
Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative Pain
Interventions
Suzetrigine, Opioid Analgesics (Tramadol or Oxycodone), Scheduled Acetaminophen and Ibuprofen
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Not applicable Interventional Results available

A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia

NCT02190903
View directory record Official record
Conditions
Postoperative Complications, Hip Fracture, Delirium
Interventions
General endotracheal anesthesia, Regional (spinal) Anesthesia
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 4, 2026, 10:26 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Integrating Financial Coaching and Smoking Cessation Coaching

NCT05154669
View directory record Official record
Conditions
Smoking
Interventions
Financial counseling, Nicotine Replacement Therapy Agent - Patches, Nicotine Replacement Therapy Agent - Lozenges, Nicotine Replacement Therapy Agent - Gum
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129
View directory record Official record
Conditions
Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 3 Interventional

Further Studies of Attention Deficit Disorder - Residual Type (RT)

NCT00693212
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 1994
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Results available

Post-transplant Flotetuzumab for AML

NCT05506956
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Flotetuzumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

NCT01458106
View directory record Official record
Conditions
Hemophilia A
Interventions
BIIB031 (rFVIIIFc), FVIII (PK subgroup only)
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Results available

Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing

NCT00156533
View directory record Official record
Conditions
Insomnia, Primary Insomnia, Psychophysiologic Insomnia
Interventions
Zolpidem, Sugar Pill
Drug
Lead sponsor
University of Rochester
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 4, 2026, 10:26 PM EDT
Not listed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials

NCT04748276
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 1 Interventional

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

NCT01456468
View directory record Official record
Conditions
Cholangitis, Sclerosing
Interventions
Oral all-trans retinoic acid (ATRA)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Targeting Anhedonia in Cocaine Use Disorder

NCT02773212
View directory record Official record
Conditions
Cocaine-Related Disorders, Anhedonia
Interventions
d-amphetamine, Contingency management, Placebo (for d-amphetamine)
Drug · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Early Phase 1 Interventional

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

NCT04280965
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Quetiapine Fumarate, Standard of care meducations
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 4, 2026, 10:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder

NCT05675735
View directory record Official record
Conditions
Problems Related to Social Environment
Interventions
Clinic-Level Multidimensional Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
4
States / cities
Storrs, Connecticut • Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Triggered Escalating Real-time Adherence (TERA) Intervention

NCT03292432
View directory record Official record
Conditions
HIV Infections
Interventions
TERA Intervention (TERA), Standard of Care (SOC)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 24 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
8
States / cities
Aurora, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 4, 2026, 10:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

NCT00140140
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer
Interventions
ABI-007, vinorelbine, Trastuzumab, G-CSF
Drug · Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 4, 2026, 10:26 PM EDT
Terminated Phase 4 Interventional Results available

Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)

NCT01938547
View directory record Official record
Conditions
Pediatric Perioperative Blood Pressure Management
Interventions
clevidipine
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Stanford, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery

NCT02423876
View directory record Official record
Conditions
Intraoperative Complication, Malignant Female Reproductive System Neoplasm, Pain
Interventions
Epidural analgesia, Intraoperative Complication Management and Prevention, Pain Therapy
Drug · Other · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 4, 2026, 10:26 PM EDT
Recruiting Not applicable Interventional

Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV

NCT06375135
View directory record Official record
Conditions
ART Adherence
Interventions
TXTXT, e-Navigation, Ecological Momentary Assessment (EMA) supported e-Navigation.
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 2Phase 3 Interventional

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

NCT02542384
View directory record Official record
Conditions
Post Abdominal Surgery Pain
Interventions
CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Sheffield, Alabama • New Haven, Connecticut • Bradenton, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

NCT03732638
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
93
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 4, 2026, 10:26 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05219513
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
RO7443904, Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Not applicable Interventional Results available

Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery

NCT02112448
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
continuous infusion, as needed dosing, Acetaminophen, ketorolac
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
3 Months to 4 Months
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 4, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Food Effect Study of 3 Types of Carisbamate

NCT04520360
View directory record Official record
Conditions
Healthy Subjects
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 4, 2026, 10:26 PM EDT
Terminated Not applicable Interventional Results available

Timing of PDA Closure and Respiratory Outcome in Premature Infants

NCT00802685
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Early ibuprofen, Late ibuprofen expectant group (placebo)
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
1 Day to 14 Days
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Sep 4, 2026, 10:26 PM EDT